Systemic magnetic targeting of pure-antiestrogen-loaded superparamagnetic nanovesicles for effective therapy of hormone-dependent breast cancers

Journal of Bioanalysis and Biomedicine

Volumn 5, Issue 2, 2013, Pages 28-35

  Plassat, Vincent ^a   Renoir, Jack Michel ^a   Autret, Gwennhael ^b   Marsaud, Veronique ^a   Menager, Christine ^c   Clement, Olivier ^b   Lesieur, Sylviane ^a  

^a UNIV PARIS SUD   (France)

^b INSERM   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; CONTRAST MEDIUM; LIPOSOME; MACROGOL; MAGNETIC FLUID LOADED LIPOSOME; NANOCRYSTAL; PHOSPHOLIPID; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; EX VIVO STUDY; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAGNETIC FIELD; MOUSE; NANOPHARMACEUTICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR XENOGRAFT;

EID: 84881541269     PISSN: None     EISSN: 1948593X     Source Type: Journal    
DOI: 10.4172/1948-593x.1000077     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, HaoY, Xu J, et al. (2009) Cancer statistics. CA Cancer J Clin 59:225-249.
2. Cufer T. (2007) Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol, 18:8-25.
3. McGuire WL, Chamness GC, Costlow ME, Richert NJ (1975) Steroids and human breast cancer. J Steroid Biochem, 6:723-727.
4. Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, et al. (1995) Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 33:19-26.
5. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, et al. (1998) Tamoxifen for prevention of reast cancer: report of the national surgical adjuvant breast and Bowel project P-1 study. J Natl Cancer Inst 90:1371-1388.
6. Jordan VC, Knudson AG (2006) Improvments in tumors targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology (Williston Park) 20:553-562.
7. Hadji P (2009) Aromatase onhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73-82.
8. Fornander T, Utqvist LE, Wilking N (1991) Effects of tamoxifen on the female genital tract. Ann N Y Acad Sci 622:469-76.
9. Eroles P, Bosch A, Bermejo B, Liuch A (2010) Mechanisms of resistance to hormonal treatment in breast cancer. Clin Trans Oncol 2:246-252.
10. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207.
11. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
12. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297-315.
13. Salzberg M, Thurlimann B, Hasler U, Delmore G, von Rohr A, et al. (2007) Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 72:147-151.
14. Andresen TL, Jensen SS, Jorgensen K (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68-97.
15. Song S, Liu D, Peng J, Sun Y, Li Z, et al. (2008) Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 363:155-161.
16. Hafeli UO (2004) Magnetically modulated therapeutic systems. Int J Pharm 277:19-24.
17. Shinkai M, Ito A (2004) Functional magnetic particles for medical application. Adv Biochem Eng Biotechnol 91:191-220.
18. Alexiou C, Schmid RJ, Jurgons R, Kremer M, Wanner G, et al. (2006) Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J 35:446-450.
19. Nobuto C, Sugita T, Kubo T, Shimose S, Yasungaga Y, et al. (2007) Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer 109:627-635.
20. Martina MS, Fortin JP, Ménager C, Clément O, Barratt G, et al. (2005) Generation of superparamgnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc 127:10676-10685.
21. Fortin-Ripoche JP, Martina MS, Gazeau F, Ménager C, Wilhelm C, et al. (2006). Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology 239:415-424.
22. Martina MS, Fortin JP, Fournier L, Ménager C, Gazeau F, et al. (2007) Magnetic targeting of rhodamine-labeled superparamagnetic liposomes to solid tumors: in vivo tracking by fibered confocal fluorscence microscopy. Mol. Imaging 6:140-146.
23. Martina MS, Nicolas V, Wilhelm C, Ménager C, Barratt G, et al. (2007) The in vitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and macrophages. Biomaterials 28:4143-4153.
24. Plassat V, Martina MS, Barratt G, Ménager C, Lesieur S (2007) Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. Int J Pharm 344:118-127.
25. Riviere C, Martina MS, Tomita Y, Wilhelm C, Tran Dinh A, et al. (2007) Magnetic targeting of nanometric magnetic-fluid-loaded liposomes to specific brain intravascular areas: a dynamic imaging study in mice. Radiology 244:439-448.
26. Martina MS, Wilhelm C, Lesieur S (2008) The effect of magnetic targeting on the uptake of magnetic-fluid-loaded liposomes by human prostatic adenocarcinoma cells. Biomaterials 29(30):4137-4145.
27. Marsaud V, Gougelet A, Maillard S, Renoir JM (2003) Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17:2013-2027.
28. Galman MS, Sundstrom, SA, Little, CR (1990) Antagonism of estrogen- and antiestrigen-induced uterine complement component C3 expression by ICI 164,384 J Steroid Biochem 36: 281-286.
29. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873.
30. Van de Velde P, Nique F, Bouchoux F, Brémaud J, Hameau MC, et al. (1994) RU 58668 A new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187-96.
31. Van de Velde P, Nique F, Brémaud J, Hameau MC, Philibert D, et al. (1995) Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment. Ann N Y Acad Sci 761:164-175.
32. Van de Velde P, Nique F, Planchon P, Prévost G, Brémaud J (1996) RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity. J Steroid Biochem Mol Biol 59:449-457.
33. Plassat V, Wilhelm C, Marsaud V, Ménager C, Gazeau F (2011) Magnetic targeting of superparamagnetic liposomes loaded with the antiestrogen RU 58668 provides a highly efficient tool for selective activity against human breast cancer cells. Adv Funct Mat 21: 83-92.
34. Massart R (1982) Preparation of aqueous magnetic liquids in alkaline and acidic media. US Patent 4329241.
35. Lesieur S, Grabielle-Madelmont C, Ménager C, Cabuil V, Dahdi D, et al. (2003) Evidence of surfactant-induced formation of transient pores in lipid bilayers by using magnetic-fluid-loaded liposomes. J Am Chem Soc 125:5266-5267.
36. Ameller T, Marsaud V, Legrand P, Gref R, Renoir JM (2003) In vivo and in vitro biological evaluation of biodegradable long circulating carriers loaded with the antiestrogen RU 58668. Int J Cancer 106:446-454.
37. Lippman M, Bolan G, HuffK (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36:4595-4601.
38. Steel CD, Stephens AL, Singletary SJ, Ciavarra RP (2008) Comparison of the lateral tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a transgenic mouse model. Lab Anim (NY) 37:26-32.
39. Renoir JM, Stella B, Amellier T, Connault E, Opolon P, et al. (2006) Improved antitumoral capacity of mixed and pure antiestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems. J Steroid Biochem Mol Biol 102:114-27.
40. Maillard S, Ameller T, Gauduchon J, Gouilleux F, Legrand P, et al. (2005) Innovative drug delivery nanosystems improve the antitumor activity in vitro and in vivo of antiestrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol 94:111-21.
41. Wilhelm C, Gazeau F, Bacri JC (2002) Magnetophoresis and ferromagnetic resonance of magnetically labeled cells. Eur Biophys J 31:118-25.